Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 8/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24608584 | 0.88 | CNR2 (0.43) | NOTUMCNR2CNR1KCNN4KMT2A | |
| SCHEMBL25460765 | 0.88 | NOTUM (0.44) | NOTUMCNR2CNR1KCNN4KMT2A | |
| SCHEMBL29175621 | 0.82 | CNR2 (0.46) | NOTUMCNR2CNR1KCNN4KMT2A | |
| SCHEMBL31121937 | 0.82 | CNR1 (0.47) | NOTUMCNR2CNR1KCNN4KMT2A | |
| SCHEMBL1866251 | 0.82 | CNR1 (0.47) | NOTUMCNR2CNR1KCNN4KMT2A | |
| SCHEMBL12678867 | 0.81 | CNR2 (0.45) | NOTUMCNR2CNR1KCNN4KMT2A | |
| SCHEMBL2067615 | 0.80 | CYP1A2 (0.43) | NOTUMCNR2CNR1SMN1; SMN2BRS3 | |
| SCHEMBL6628 | 0.80 | KMT2A (0.49) | CNR2CNR1KCNN4KMT2ASMN1; SMN2 | |
| SCHEMBL15515852 | 0.79 | CNR2 (0.50) | CNR2CNR1KCNN4LMNAPLCG1 | |
| SCHEMBL15458985 | 0.79 | CNR2 (0.36) | NOTUMCNR2CNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938114-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-05-13 | — | — | US | disclosed |
| US-10836706-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190055188-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2019-02-21 | — | — | US | disclosed |
| WO-2018165614-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2017147335-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147335-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-1558577-B1 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1558577-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004005256-A2 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938114-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | NOTUM 1536/4885CNR2 4288/4885CNR1 3708/4885 |
| US-10836706-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | NOTUM 1536/4885CNR2 4288/4885CNR1 3708/4885 |
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | NOTUM 2460/4885CNR2 147/4885CNR1 56/4885 |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | NOTUM 1536/4885CNR2 4288/4885CNR1 3708/4885 |
| US-20190055188-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | NOTUM 1536/4885CNR2 4288/4885CNR1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.